Company attributes
Other attributes
Pandion Therapeutics, Inc., is a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, it is also known as MSD outside the United States and Canada. Pandion Therapeutics Inc is a clinical-stage biopharmaceutical company that is engaged in developing novel therapeutics for addressing the challenging needs of patients who are suffering from autoimmune diseases.
This company combined a network-based conceptualization of the immune system in protein engineering to create Therapeutic Autoimmune regulatory protein drug design and discovery platform. Its pipeline product is PT101, which is used for treating patients with moderate and severe ulcerative colitis and treating patients with systemic lupus erythematosus, others are PT627, PT001, and more.
The portfolio of Pandion also includes PD-1 agonists which are in the development stage for several autoimmune diseases. Pandion applied its TALON technology to build a pipeline of candidates that are designed to re-balance the immune response with potential applications across a broad array of autoimmune diseases.
